Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 34687957)

  • 1. Cartilage Oligomeric Matrix Protein, COMP may be a Better Prognostic Marker Than CEACAM5 and Correlates With Colon Cancer Molecular Subtypes, Tumor Aggressiveness and Overall Survival.
    Wusterbarth E; Chen Y; Jecius H; Krall E; Runyan RB; Pandey R; Nfonsam V
    J Surg Res; 2022 Feb; 270():169-177. PubMed ID: 34687957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing Incidence of Colon Cancer in the Young: Assessing the Tumor Biology.
    Nfonsam VN; Jecius H; Chen D; Omesiete PN; Ewongwo AN; Elquza E; Scott AJ; Jandova J
    J Am Coll Surg; 2019 Jul; 229(1):79-90. PubMed ID: 30995524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cartilage oligomeric matrix protein (COMP) promotes cell proliferation in early-onset colon cancer tumorigenesis.
    Nfonsam VN; Jecius HC; Janda J; Omesiete PN; Elquza E; Scott AJ; Nfonsam LE; Jandova J
    Surg Endosc; 2020 Sep; 34(9):3992-3998. PubMed ID: 31617091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types.
    Guo B; Wang Y; Liu W; Zhang S
    Clin Transl Oncol; 2023 Feb; 25(2):535-554. PubMed ID: 36255654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cartilage oligomeric matrix protein is a prognostic factor and biomarker of colon cancer and promotes cell proliferation by activating the Akt pathway.
    Liu TT; Liu XS; Zhang M; Liu XN; Zhu FX; Zhu FM; Ouyang SW; Li SB; Song CL; Sun HM; Lu S; Zhang Y; Lin J; Tang HM; Peng ZH
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1049-1063. PubMed ID: 29560517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COMP Gene Coexpresses With EMT Genes and Is Associated With Poor Survival in Colon Cancer Patients.
    Nfonsam VN; Nfonsam LE; Chen D; Omesiete PN; Cruz A; Runyan RB; Jandova J
    J Surg Res; 2019 Jan; 233():297-303. PubMed ID: 30502262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification.
    Pilati C; Taieb J; Balogoun R; Marisa L; de Reyniès A; Laurent-Puig P
    Ann Oncol; 2017 May; 28(5):1032-1035. PubMed ID: 28328000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection and clinical significance of CEACAM5 methylation in colorectal cancer patients.
    Huang SC; Chang SC; Liao TT; Yang MH
    Cancer Sci; 2024 Jan; 115(1):270-282. PubMed ID: 37942534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cartilage oligomeric matrix protein contributes to the development and metastasis of breast cancer.
    Englund E; Bartoschek M; Reitsma B; Jacobsson L; Escudero-Esparza A; Orimo A; Leandersson K; Hagerling C; Aspberg A; Storm P; Okroj M; Mulder H; Jirström K; Pietras K; Blom AM
    Oncogene; 2016 Oct; 35(43):5585-5596. PubMed ID: 27065333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.
    Marisa L; de Reyniès A; Duval A; Selves J; Gaub MP; Vescovo L; Etienne-Grimaldi MC; Schiappa R; Guenot D; Ayadi M; Kirzin S; Chazal M; Fléjou JF; Benchimol D; Berger A; Lagarde A; Pencreach E; Piard F; Elias D; Parc Y; Olschwang S; Milano G; Laurent-Puig P; Boige V
    PLoS Med; 2013; 10(5):e1001453. PubMed ID: 23700391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The myeloid cell biomarker EMR1 is ectopically expressed in colon cancer.
    Ali H; Olsson L; Lindmark G; Hammarström ML; Hammarström S; Sitohy B
    Tumour Biol; 2021; 43(1):209-223. PubMed ID: 34486997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.
    Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E
    Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of Cartilage Oligomeric Matrix Protein in colorectal cancer is an adverse prognostic factor and correlates negatively with infiltrating immune cells and PD-L1 expression.
    Blom AM; Gialeli C; Hagerling C; Berntsson J; Jirström K; Papadakos KS
    Front Immunol; 2023; 14():1167659. PubMed ID: 37207219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cartilage oligomeric matrix protein overexpression is an independent poor prognostic indicator in patients with intrahepatic cholangiocarcinoma.
    Ong KH; Hsieh YY; Lai HY; Sun DP; Chen TJ; Huang SK; Tian YF; Chou CL; Shiue YL; Wu HC; Chan TC; Tsai HH; Li CF; Su PA; Kuo YH
    Sci Rep; 2023 Oct; 13(1):17444. PubMed ID: 37838792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic subtypes predict outcomes in colorectal cancer.
    Kasurinen J; Beilmann-Lehtonen I; Kaprio T; Hagström J; Haglund C; Böckelman C
    Acta Oncol; 2023 Mar; 62(3):245-252. PubMed ID: 36867078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional proteomics of colon cancer Consensus Molecular Subtypes.
    Feliu J; Gámez-Pozo A; Martínez-Pérez D; Pérez-Wert P; Matamala-Luengo D; Viñal D; Kunz L; López-Vacas R; Dittmann A; Rodríguez-Salas N; Custodio A; Fresno Vara JÁ; Trilla-Fuertes L
    Br J Cancer; 2024 Jun; 130(10):1670-1678. PubMed ID: 38486123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FBW7 suppresses metastasis of colorectal cancer by inhibiting HIF1α/CEACAM5 functional axis.
    Li Q; Li Y; Li J; Ma Y; Dai W; Mo S; Xu Y; Li X; Cai S
    Int J Biol Sci; 2018; 14(7):726-735. PubMed ID: 29910683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of CEACAM5 as a Biomarker for Prewarning and Prognosis in Gastric Cancer.
    Zhou J; Fan X; Chen N; Zhou F; Dong J; Nie Y; Fan D
    J Histochem Cytochem; 2015 Dec; 63(12):922-30. PubMed ID: 26374829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRT19 and CEACAM5 mRNA-marked circulated tumor cells indicate unfavorable prognosis of breast cancer patients.
    Wang XM; Zhang Z; Pan LH; Cao XC; Xiao C
    Breast Cancer Res Treat; 2019 Apr; 174(2):375-385. PubMed ID: 30535933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer.
    Tarazona N; Gimeno-Valiente F; Gambardella V; Huerta M; Roselló S; Zuniga S; Calon A; Carbonell-Asins JA; Fontana E; Martinez-Ciarpaglini C; Eason K; Rentero-Garrido P; Fleitas T; Papaccio F; Moro-Valdezate D; Nyamundanda G; Castillo J; Espí A; Sadanandam A; Roda D; Cervantes A
    ESMO Open; 2020 Sep; 5(5):e000847. PubMed ID: 32967918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.